Bovine Mastitis Market Size & Share 2026-2035

Bovine Mastitis Market Size

The bovine mastitis market was valued at USD 2.2 billion in 2025. The market is estimated to grow from USD 2.3 billion in 2026 to USD 4 billion in 2035, growing at a CAGR of 6.5% over the analysis period, according to the latest report published by Global Market Insights Inc.

This market growth is driven by the rising incidence of mastitis in dairy cattle and the growing need for quality milk production. For example, the Organisation for Economic Co-operation and Development (OECD) forecasts that approximately 80% of global milk production between 2020 and 2029 will be from cow milk, thereby emphasizing the need for udder health to maintain productivity in the dairy sector. Since mastitis is one of the most important diseases affecting dairy cattle, the need for efficient diagnostic, therapeutic, and preventive strategies has been increasing steadily, thereby boosting the growth of the market.

In addition, increased awareness about animal health and welfare, as well as a growing need to minimize economic losses due to mastitis, has further accelerated the demand for improved treatment strategies. Furthermore, advances in veterinary diagnostics, such as rapid test kits and on-farm diagnostic tools, have improved the early detection and management of the disease. Increased investment in R&D activities to develop improved vaccines, antibiotics, and natural antimicrobial agents also supports the growth of the market. Government programs focused on improving livestock productivity and modernizing the dairy industry further support the market share.
 

Bovine mastitis refers to the inflammation of the udder tissue in dairy cows, mainly due to bacterial infections that affect milk quality and production. Bovine mastitis is one of the most prevalent and economically important diseases in dairy cattle, necessitating prompt diagnosis and appropriate treatment strategies. The bovine mastitis market encompasses diagnostic, treatment, and preventive measures intended to optimize animal health outcomes and mitigate production losses.
 

Furthermore, the market has been steadily expanding, rising from USD 1.8 billion in 2022 to an estimated USD 2 billion in 2024, with a forecast reaching USD 4 billion by 2035. This is due to the increasing number of mastitis cases, the rising global dairy production, advances in mastitis diagnostic technology, and the development of novel treatment compositions that optimize treatment potency and adherence among farmers.
 

Some of the prominent players in the market include Zoetis, Merck Animal Health, Boehringer Ingelheim, and Ceva, among others. These players make significant contributions to the growth of the market through their comprehensive product offerings, global reach, and continued investment in veterinary research and development.

Bovine Mastitis Market Trends

• The bovine mastitis industry is growing due to advancements in mastitis diagnosis, increasing incidence of mastitis, and increasing awareness about animal welfare.
   
• Mastitis is still recognized as one of the most prevalent diseases in dairy cows, with 25-30% of cows being affected yearly, resulting in substantial economic loss in various regions of the world.
   
• According to the National Institutes of Health (NIH), the total annual economic loss to U.S. dairy farmers due to mastitis is estimated to be between USD 400 and USD 500 million, which is equivalent to around USD 23 per cow. This emphasizes the need for improved mastitis management to reduce economic losses.
   
• Further, partnerships and collaborations between pharmaceutical and biotech companies drive the market growth. For example, Amicogen has partnered with Lysando to address the challenge of mastitis in dairy cows caused by multi-resistant bacteria. This collaboration leverages Amicogen’s industrial enzyme expertise and Lysando’s antimicrobial Artilysin technology. This reflects a growing trend towards innovative, non-antibiotic treatments to enhance animal health.
   
• Moreover, technological advancements in diagnostic methods have fueled the growth of this market. For instance, an article published in the National Library of Medicine in July 2023 illustrates the use of PCR, acute phase protein analysis, ELISA, and qPCR, which improves the accuracy and specificity of pathogen detection, even at the subspecies level. This enables more targeted and effective treatment strategies.  
   
• Similarly, in June 2024, IIT Kanpur’s mastitis detection technology, transferred to Prompt Equipments which focuses on the cow’s health conditions by speeding up and fine-tuning diagnosis to enable proactive intervention and treatment. This innovation aligns with the trend of advanced diagnostics, enhancing accuracy and herd health in the bovine mastitis market.
   
• Moreover, the use of AI and digitalized record-keeping is revolutionizing the concept of precision livestock farming, which makes it possible to monitor and treat livestock in real-time.
   
• For example, Australia’s Clinical Mastitis Decision Support Tool Project, which brings together dairy farmers, industry experts and researchers into a USD 3.5 million project. It offers precise diagnostics to minimize antibiotic therapy, provide tailored solutions, and combines data with Dairy Industry’s DataVat platform for active mastitis control.
   
• As dairy farmers comprehend that the health of animals is proportional to the quantity of milk produced, there is an increased focus on proactive management and routine mastitis examinations. Industry players are promoting herd management practices that reduce infection risk and improve milk quality.
   
• Furthermore, the development of precision livestock farming technology is making it simpler to track the health of dairy cows, making it possible to treat mastitis early. Additionally, in established dairy markets, there is a growing trend towards automated milking and wearable sensors.
   

Bovine Mastitis Market Analysis

Based on the product, the market is segmented into pharmaceutical and diagnostics. The pharmaceutical segment further bifurcated into antibiotics, vaccines and other pharmaceuticals. The pharmaceutical segment dominated the market with USD 1.7 billion in 2025.  
 

• The pharmaceutical segment focuses on developing treatments to combat infections in dairy cattle. This veterinary medicine segment covers antibiotic and anti-inflammatory drug usage and supportive therapy to control clinical and subclinical mastitis.
   
• Penicillin and cephalosporin are the most common antibiotics used in mastitis treatment. Innovations in intramammary infusion treatments continue to enhance treatment efficacy.
   
• Further, innovation of new drugs and therapies in veterinary medicine has increased market growth because it expands the treatment options that can be provided.
   
• Also, the availability of advanced drug formulations and novel biologic drugs further enhances the market growth. Pharmaceutical industries are also researching combination therapies to increase compliance and eliminate resistance whilst boosting milk safety.

Based on type, the bovine mastitis market is divided into clinical mastitis, and sub-clinical mastitis. The clinical mastitis segment accounted for a significant market share of 54.9% in 2025.       
 

• Clinical mastitis is a key segment of this market because of possible milk yield reduction and its visible symptoms. The Canadian Bovine Mastitis Research Network (CBMRN) conducted a study on 41 herds comprising of 458 dairy cows, which revealed that the incidence of clinical mastitis stood at 26.3 per 100 cows. This highlights the importance of diagnosis and treatment of clinical mastitis.
   
• The increasing necessity to treat clinical mastitis along with the growing availability of drugs and awareness is accelerating its treatment on a global scale. More dairy farms are now beginning to utilize automated milking as well as clinical mastitis detection systems.
   
• Due to growing cases of antimicrobial resistance, there is an increasing demand for non-antibiotic therapies that include probiotics, vaccines, and herbal medicines.
   
• For example, Mastirak Gel, a poly-herbal medicine designed by National Innovation Foundation (NIF) is used to improve udder health, reduce inflammation and minimize antibiotic usage while managing costs. This innovation highlights the potential of herbal medicines in the market.
   

Based on route of administration, the bovine mastitis market is divided into intra-mammary, and systemic. The intra-mammary segment dominated the market with USD 1.2 billion in 2025.       
 

• The intra-mammary segment is important in improving infection management at the level of the infected udder tissues. It consists of antibiotics, anti-inflammatory agents and teat sealants used for mastitis infections management and prevention.
   
• There is also increasing use of teat sealants to avert infections during the dry period mastitis, which is gaining attention in the segment. Automated milking and monitoring systems further enhance treatment precision.
   
• Also, over the last few years, there has been increasing regulatory control concerning the misuse of antibiotics, leading to more innovation in non-antibiotic intramammary therapies, including natural medicine.
   

Based on end use, the bovine mastitis market is divided into veterinary hospitals and clinics, diagnostic laboratories, and other end users. The veterinary hospitals and clinics segment dominated the market in 2025 and is expected to reach 2 billion by 2035.   
 

• Veterinary hospitals and clinics play important role in disease diagnosis and treatment, as well as prevention. These facilities have lab-based mastitis diagnostics along with other more advanced imaging and treatment options available at the facility.
   
• Dairy farmers are changing their practices due to increasing knowledge of mastitis prevention and early intervention, which has made them willing to use professional veterinary services. This segment also enhances farmers’ knowledge on milking hygiene, antibiotic treatment, and other routine preventive measures.
   
• Additionally, veterinary hospitals have started using digital health records and monitoring devices on farms to develop specific mastitis control programs, ensuring better dairy herd health outcomes.
   
• The diagnostic laboratories segment held second highest market share with a revenue of USD 676.8 million in 2025, primarily driven by increasing adoption of early detection technologies and advanced testing methods that enable faster, more accurate mastitis identification, improving herd‑health decision‑making and treatment outcomes.

North America Bovine Mastitis Market

North America bovine mastitis industry was valued at USD 834.7 million in 2025 and is anticipated to grow at a CAGR of 6.3% over the forecast years.  
 

• North America’s market is driven by a highly developed dairy sector, strong awareness of udder‑health management, and widespread adoption of advanced treatment and diagnostic solutions.
   
• The region benefits from stringent milk‑quality regulations and strong veterinary infrastructure, encouraging preventive care, rapid testing, and improved farm hygiene practices.
   
• Veterinary hospitals and clinics also play a key role by offering comprehensive diagnostic and therapeutic services. Collectively, these factors position North America as a technologically progressive and prevention‑focused mastitis‑management market.
   

The U.S. dominated the North America bovine mastitis market with a revenue of USD 648.3 million and USD 683 million in 2022 and 2023, respectively. The market was valued at USD 759.2 million in 2025 and grew from USD 720 million in 2024.   
 

• U.S. have high population of livestock animals which drives the market growth in the country. For example, as per U.S. Department of Agriculture (USDA), there were 87.2 million head of cattle and calves on the U.S. farms as of January 2024.
   
• Further, in the U.S., the demand for good quality milk has spurred comprehensive dairy farming coupled with sophisticated veterinary services. Significant expansion of dairy industry is reason for market growth.
   
• For instance, the U.S. Department of Agriculture (USDA) reports that in 2022 there was an increase of approximately 34,000 dairy farms in the U.S. This trend has increased the adoption of rapid diagnostics, efficient intramammary antibiotics, and non-antibiotic intramammary therapies.
   
• In efforts to lower the levels of antibiotic resistance, the U.S. employs innovative approaches including the use of vaccines and probiotics. Governmental organizations like FDA supervise the use of antibiotics.
   
• The market is also affected by increased health consciousness and the increased use of farm automation technologies. There is a great concentration of these industries with many offering a wide variety of treatment and prevention measures for dairy farmers in the U.S.   
   

Europe Bovine Mastitis Market

Europe market accounted for USD 605.2 million in 2025 and is anticipated to show lucrative growth over the forecast period.
 

• Rising animal adoption in European region coupled with increasing initiatives by government to improve animal healthcare is anticipated to spur market growth.
   
• Moreover, advancements in veterinary medicine with frequent introduction and approval of novel pharmaceuticals will boost the demand for bovine mastitis in the Europe region.
   
• Also, the presence of highly equipped veterinary clinics and hospitals in Germany, UK, and France, further boosts the Europe market.
   

The Germany bovine mastitis market is experiencing robust growth in Europe.  
 

• The German market for bovine mastitis is influenced by the quality milk production standards. Farmers are proactive, resulting in the widespread use of prior-use teat sealants and probiotics and other natural products.
   
• The German dairy industry has also benefited from the government’s investment into the research of detection and treatment of mastitis diseases. Furthermore, Germany’s shift to organic farming is increasing the need for sustainable and green solutions to mastitis control challenges.   
   

Asia Pacific Bovine Mastitis Market

The Asia Pacific market witnessed substantial growth of 6.8% during the analysis period.
 

• The bovine mastitis market in the Asia Pacific region is growing rapidly due to the advancements in animal health awareness, and the improvement of veterinary care infrastructure.
   
• Additionally, rise in the number of veterinary clinics and hospitals coupled with government policies aimed at animal health care contribute to the rapid growth of the market in the region.
   
• Moreover, presence of both international market players and local regional manufacturers intensifies the market competition, further driving the regional market growth.
   

China bovine mastitis market is poised to witness high growth over the analysis period.
 

• China’s market is expanding rapidly due to the increasing dairy consumption and substantial cattle population of the country. The use of modern veterinary services, as well as the overall milking and disease monitoring practices in China is improving.
   
• While modern antibiotics are available, China needs more regulatory control to help limit the overuse of medications and further encourage the use of vaccines and herbal supplements.
   

Latin America Bovine Mastitis Market

The Brazil bovine mastitis industry is experiencing robust growth in Latin America.
 

• Brazil’s bovine mastitis industry is primarily influenced by its large dairy industry and tropical climate, which creates conditions for higher mastitis prevalence. There is an increasing shift towards the use of the routine prescription of anti-inflammatory drugs and hygienic milking.
   
• There are national and enterprise level mastitis control programs and farmer training programs for enhancing milk quality, which are pioneered by the government and industry associations in Brazil. In addition, there is more spending on farm machinery and computerized management of livestock related illnesses.
   

Middle East and Africa Bovine Mastitis Market

The Saudi Arabia bovine mastitis industry is witnessing substantial growth in Middle East and Africa.
 

• Increased investment in the dairy industry coupled with climate challenges is propelling growth for Saudi Arabia bovine mastitis industry . Increased usage of antibiotics, vaccines, and better milking sanitation techniques are on the rise.
   
• The government’s focus on food security and dairy self-sufficiency supports investments in dairy health innovations. High-value dairy production has led to the adoption of farm automation, mastitis diagnostics, and data-driven disease surveillance.  
   

Bovine Mastitis Market Share

The top 5 companies in the bovine mastitis industry accounted for combined market share of around 62% in 2025, with Zoetis leading the industry, followed by Boehringer Ingelheim, Merck, Virbac, and Elanco. These companies dominate the market through strategic acquisitions, continuous innovation, and expanding product portfolios. These companies offer solutions for mastitis prevention, diagnostics, and treatment.
 

Furthermore, to expand their market presence, key players are actively forming partnerships and collaborations with biotech firms, pharmaceutical companies, and research institutions. Companies such as HIPRA focus on developing vaccines, while DeLaval make diagnostics solutions. To maintain competitive edge, companies are actively investing in research and development.
 

Bovine Mastitis Market Companies

Major players operating in the bovine mastitis industry are:

• Advanced Animal Diagnostics
• Boehringer Ingelheim
• Ceva
• DeLaval
• Elanco
• Heilsaa
• HIPPRA
• ImmuCell
• Merck
• Norbrook
• Virbac
• Zoetis
   
• Boehringer Ingelheim

Boehringer Ingelheim focuses on immune-enhancing mastitis solutions. For example, its Ubrolexin intramammary antibiotic are widely used for mastitis recovery and prevention.
 

• Zoetis

Zoetis offers an extensive portfolio of bovine mastitis treatments, including antibiotics and vaccines like Spectramast LC, which targets clinical mastitis during lactation.
 

• DeLaval

DeLaval provides innovative milking systems and mastitis management solutions. Its DeLaval VMS milking robots integrate automatic detection of mastitis symptoms, ensuring timely intervention.
 

Bovine Mastitis Industry News

• In August 2023, Zoetis launched Vetscan Mastigram+, the first rapid on‑farm mastitis diagnostic, enabling dairy farmers to detect Gram‑positive mastitis pathogens within eight hours. This innovation supports targeted antimicrobial use, reduces unnecessary treatments, and helps improve milk quality and udder health outcomes in dairy herds.
   
• In September 2022, Boehringer Ingelheim introduced new susceptibility testing criteria for Ubrolexin, aimed at optimizing its effectiveness in treating mastitis in dairy cows. This update enhances precision in targeting mastitis-causing pathogens, promoting improved treatment outcomes and udder health in dairy herds.
   
• In January 2022, DeLaval launched the Evanza cluster, a milking solution designed to improve teat health and reduce mastitis rates in dairy cattle. This innovation aims to enhance milk production efficiency and support bovine mastitis prevention efforts in the dairy industry.
   
• In April 2021, Boehringer Ingelheim expanded its dairy mastitis portfolio by introducing a blue internal teat sealant. This product aims to enhance mastitis prevention and improve udder health by providing an effective barrier against bacterial infections in dairy cows.
   

The bovine mastitis market research report includes in-depth coverage of the industry with estimates and forecasts in terms of revenue in USD Million from 2022 - 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Pharmaceutical
  • Antibiotics
  • Vaccines
  • Other pharmaceuticals
• Diagnostics

Market, By Type

• Clinical mastitis
• Sub-clinical mastitis

Market, By Route of Administration

• Intra-mammary
• Systemic

Market, By End Use

• Veterinary hospitals and clinics
• Diagnostic laboratories
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea

• Latin America
  • Brazil
  • Mexico
  • Argentina

• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE